Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)

NCT01212094 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
44
Enrollment
NIH
Sponsor class

Stopped The efficacy on CSF biomarkers failed to reach criteria for continuation of the trial

Conditions

Interventions

Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)